Dapagliflozin Improves Glucose Outcomes in Type 1 Diabetes

FRIDAY, April 26, 2019 -- In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in Diabetes Care. Chantal Mathieu,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news